Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130

Identification and characterization of a new member of the TNF family that induces apoptosis

Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290

Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family

Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,777

Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation

Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schönfeld, H., Broger, C., Loetscher, H., & Lesslauer, W. (1993) · Cell · doi:10.1016/0092-8674(93)90132-a · Cited by 1,097

TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells

Wong, B. R., Rho, J., Arron, J. R., Robinson, E. A., Orlinick, J. R., Chao, M. V., Kalachikov, S. M., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042

Modulation of Osteoclast Differentiation

Suda, T., Takahashi, N., & Martin, T. J. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-66 · Cited by 1,004

Osteoclast-Like Cell Formation and its Regulation by Osteotropic Hormones in Mouse Bone Marrow Cultures*

Takahashi, N., Yamana, H., Yoshiki, S., Roodman, G. D., Mundy, G. R., Jones, S. J., BOYDE, A., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-122-4-1373 · Cited by 731

Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95

Chinnaiyan, A. M., O’Rourke, K. M., Yu, G.-L., Lyons, R. H., Garg, M., Duan, D. R., Xing, L., Gentz, R., Ni, J., & Dixit, V. M. (1996) · Science · doi:10.1126/science.274.5289.990 · Cited by 653

Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes

Horton, J. E., Raisz, L. G., Simmons, H. A., Oppenheim, J. J., & Mergenhagen, S. E. (1972) · Science · doi:10.1126/science.177.4051.793 · Cited by 565

IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss

Ruocco, M. G., Maeda, S., Park, J. M., Lawrence, T., Hsu, L.-C., Cao, Y., Schett, G., Wagner, E. F., & Karin, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042081 · Cited by 252

Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells

Streicher, C., Heyny, A., Andrukhova, O., Haigl, B., Slavic, S., Schüler, C., Kollmann, K., Kantner, I., Sexl, V., Kleiter, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06614-0 · Cited by 251

Inflammatory osteolysis: A conspiracy against bone

Mbalaviele, G., Novack, D. V., Schett, G., & Teitelbaum, S. L. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93356 · Cited by 251

The Role of Receptor Activator of Nuclear Factor-κB (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications

Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246

Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice

Yao, W., Cheng, Z., Busse, C., Pham, A., Nakamura, M. C., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23454 · Cited by 241

Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand.

Hikita, A., Yana, I., Wakeyama, H., Nakamura, M., Kadono, Y., Oshima, Y., Nakamura, K., Seiki, M., & Tanaka, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606656200 · Cited by 236

Osteoprotegerin and RANK ligand expression in prostate cancer.

Brown, J. M., Corey, E., Lee, Z. D., True, L. D., Yun, T. J., Tondravi, M., & Vessella, R. L. (2001) · Urology · doi:10.1016/s0090-4295(00)01122-5 · Cited by 234

The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma

Heymann, M.-F., Lézot, F., & Heymann, D. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.011 · Cited by 233

IL-1 plays an important role in the bone metabolism under physiological conditions

Lee, Y.-M., Fujikado, N., Manaka, H., Yasuda, H., & Iwakura, Y. (2010) · International Immunology · doi:10.1093/intimm/dxq431 · Cited by 226

RANK Signaling Is Not Required for TNFα-Mediated Increase in CD11bhi Osteoclast Precursors but Is Essential for Mature Osteoclast Formation in TNFα-Mediated Inflammatory Arthritis

Li, P., Schwarz, E. M., O'Keefe, R. J., Ma, L., Boyce, B. F., & Xing, L. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301233 · Cited by 220

PU.1 target genes undergo Tet2-coupled demethylation and DNMT3b-mediated methylation in monocyte-to-osteoclast differentiation

de la Rica, L., Rodríguez-Ubreva, J., García, M., Islam, A. B., Urquiza, J. M., Hernando, H., Christensen, J., Helin, K., Gómez-Vaquero, C., & Ballestar, E. (2013) · Genome Biology · doi:10.1186/gb-2013-14-9-r99 · Cited by 211

Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κB Ligand: Clinical Utility in Metabolic Bone Disease Assessment

Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215

Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint

Haynes, D. R., Crotti, T. N., Loric, M., Bain, G. I., Atkins, G. J., & Findlay, D. M. (2001) · Rheumatology · doi:10.1093/rheumatology/40.6.623 · Cited by 216

Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus*

Ikeda, T., Kasai, M., Utsuyama, M., & Hirokawa, K. (2001) · Endocrinology · doi:10.1210/endo.142.4.8070 · Cited by 215

RANKL/OPG; Critical role in bone physiology

Martin, T. J., & Sims, N. A. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9308-6 · Cited by 213

Regulation of energy metabolism by the skeleton: osteocalcin and beyond

Ferron, M., & Lacombe, J. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.05.022 · Cited by 211

Pathophysiology and treatment of osteoporosis: Challenges for clinical practice in older people

Barnsley, J., Buckland, G., Chan, P. E., Ong, A., Ramos, A. S., Baxter, M., Laskou, F., Dennison, E. M., Cooper, C., & Patel, H. P. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01817-y · Cited by 199

Correlates of osteoprotegerin levels in women and men.

Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L. (2002) · Osteoporosis International · doi:10.1007/s001980200045 · Cited by 205

Hedgehog Signaling in Mature Osteoblasts Regulates Bone Formation and Resorption by Controlling PTHrP and RANKL Expression

Mak, K. K., Bi, Y., Wan, C., Chuang, P.-T., Clemens, T., Young, M., & Yang, Y. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.02.003 · Cited by 202

Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling

Wei, S., Wang, M. W.-H., Teitelbaum, S. L., & Ross, F. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104957200 · Cited by 202

Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.

Michael, H., Härkönen, P. L., Väänänen, H. K., & Hentunen, T. A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050803 · Cited by 200

Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function.

Yun, T. J., Tallquist, M. D., Aicher, A., Rafferty, K. L., Marshall, A. J., Moon, J. J., Ewings, M. K., Mohaupt, M., Herring, S. W., & Clark, E. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1482 · Cited by 195

17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α.

Saika, M., Inoue, D., Kido, S., & Matsumoto, T. (2001) · Endocrinology · doi:10.1210/endo.142.6.8220 · Cited by 194

Smoking and inflammation: evidence for a synergistic role in chronic disease

Johannsen, A., Susin, C., & Gustafsson, A. (2014) · Periodontology 2000 · doi:10.1111/j.1600-0757.2012.00456.x · Cited by 194

Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.

Crotti, T. N., Smith, M. D., Weedon, H., Ahern, M. J., Findlay, D. M., Kraan, M., Tak, P. P., & Haynes, D. R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.12.1047 · Cited by 186

A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3.

Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1478 · Cited by 187

Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids.

Vidal, N., Brandstrom, H., Jonsson, K., & Ohlsson, C. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1590191 · Cited by 185

Transcriptional Program of Mouse Osteoclast Differentiation Governed by the Macrophage Colony-stimulating Factor and the Ligand for the Receptor Activator of NFκB

Cappellen, D., Luong-Nguyen, N.-H., Bongiovanni, S., Grenet, O., Wanke, C., & Šuša, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200434200 · Cited by 184

The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction.

Geusens, P. P., Landewé, R. B. M., Garnero, P., Chen, D., Dunstan, C. R., Lems, W. F., Stinissen, P., van der Heijde, D. M. F. M., van der Linden, S., & Boers, M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21896 · Cited by 182

Pituitary Diseases and Bone

Mazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181

Regulation of osteoclast function and bone mass by RAGE

Zhou, Z., Immel, D., Xi, C.-X., Bierhaus, A., Feng, X., Mei, L., Nawroth, P., Stern, D. M., & Xiong, W.-C. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051947 · Cited by 178

Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.

Cao, J., Venton, L., Sakata, T., & Halloran, B. P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.270 · Cited by 173

RANKL as the master regulator of osteoclast differentiation

Takayanagi, H. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01191-1 · Cited by 175

NF-κB p50 and p52 Expression Is Not Required for RANK-Expressing Osteoclast Progenitor Formation but Is Essential for RANK- and Cytokine-Mediated Osteoclastogenesis

Xing, L., Bushnell, T. P., Carlson, L., Tai, Z., Tondravi, M., Siebenlist, U., Young, F., & Boyce, B. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1200 · Cited by 165

HMGB1 Regulates RANKL-Induced Osteoclastogenesis in a Manner Dependent on RAGE

Zhou, Z., Han, J.-Y., Xi, C.-X., Xie, J.-X., Feng, X., Wang, C.-Y., Mei, L., & Xiong, W.-C. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080234 · Cited by 160

17β-Estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells

Bengtsson, A. K., Ryan, E. J., Giordano, D., Magaletti, D. M., & Clark, E. A. (2004) · Blood · doi:10.1182/blood-2003-10-3380 · Cited by 161

Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls.

Haynes, D. R. (2003) · Rheumatology · doi:10.1093/rheumatology/keg047 · Cited by 157

Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget’s disease of bone.

Menaa, C., Reddy, S. V., Kurihara, N., Maeda, H., Anderson, D., Cundy, T., Cornish, J., Singer, F. R., Bruder, J. M., & Roodman, G. D. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9133 · Cited by 154

CD44 and β3 Integrin Organize Two Functionally Distinct Actin-based Domains in Osteoclasts

Chabadel, A., Bañon-Rodríguez, I., Cluet, D., Rudkin, B. B., Wehrle-Haller, B., Genot, E., Jurdic, P., Anton, I. M., & Saltel, F. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-04-0378 · Cited by 154

Osteoprotegerin: Multiple partners for multiple functions

Baud’huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., Redini, F., Heymann, M.-F., & Heymann, D. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.06.001 · Cited by 153

RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation

Chen, X., Zhi, X., Wang, J., & Su, J. (2018) · Bone Research · doi:10.1038/s41413-018-0035-6 · Cited by 154

RANKL protein is expressed at the pannus–bone interface at sites of articular bone erosion in rheumatoid arthritis

Pettit, A. R., Walsh, N. C., Manning, C., Goldring, S. R., & Gravallese, E. M. (2006) · Rheumatology · doi:10.1093/rheumatology/kel045 · Cited by 151

Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells

Grigoriadis, A. E., Kennedy, M., Bozec, A., Brunton, F., Stenbeck, G., Park, I.-H., Wagner, E. F., & Keller, G. M. (2010) · Blood · doi:10.1182/blood-2009-07-234690 · Cited by 151

Soluble RANKL and risk of nontraumatic fracture.

Schett, G. (2004) · JAMA · doi:10.1001/jama.291.9.1108 · Cited by 146

Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood

Sørensen, M. G., Henriksen, K., Schaller, S., Henriksen, D. B., Nielsen, F. C., Dziegiel, M. H., & Karsdal, M. A. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0725-9 · Cited by 143

Estrogen deficiency, T cells and bone loss

Pacifici, R. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2007.06.008 · Cited by 146

Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss

Xiong, J., Cawley, K., Piemontese, M., Fujiwara, Y., Zhao, H., Goellner, J. J., & O’Brien, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-05244-y · Cited by 144

RANK ligand is a prerequisite for cancer-associated osteolytic lesions.

Kitazawa, S., & Kitazawa, R. (2002) · The Journal of Pathology · doi:10.1002/path.1199 · Cited by 141

New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis

Crockett, J. C., Mellis, D. J., Scott, D. I., & Helfrich, M. H. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1272-8 · Cited by 143

Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.

Mancino, A. T., Klimberg, V. S., Yamamoto, M., Manolagas, S. C., & Abe, E. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6204 · Cited by 138

Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death

Bezzi, M., Hasmim, M., Bieler, G., Dormond, O., & Rüegg, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308114200 · Cited by 139

OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.

Kostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., & Dunstan, C. R. (2001) · Endocrinology · doi:10.1210/endo.142.10.8437 · Cited by 140

Activation of extracellular signal-regulated kinase is involved in mechanical strain inhibition of RANKL expression in bone stromal cells.

Rubin, J., Murphy, T. C., Fan, X., Goldschmidt, M., & Taylor, W. R. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.8.1452 · Cited by 131

The Ratio of Messenger RNA Levels of Receptor Activator of Nuclear Factor κB Ligand to Osteoprotegerin Correlates with Bone Remodeling Indices in Normal Human Cancellous Bone but Not in Osteoarthritis

Fazzalari, N. L., Kuliwaba, J. S., Atkins, G. J., Forwood, M. R., & Findlay, D. M. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.6.1015 · Cited by 129

The Osteoblast to Osteocyte Transition: Epigenetic Changes and Response to the Vitamin D3Hormone

St. John, H. C., Bishop, K. A., Meyer, M. B., Benkusky, N. A., Leng, N., Kendziorski, C., Bonewald, L. F., & Pike, J. W. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1091 · Cited by 127

Osteoprotegerin and RANKL in the pathogenesis of Thalassemia-induced osteoporosis: new pieces of the puzzle.

Morabito, N., Gaudio, A., Lasco, A., Atteritano, M., Pizzoleo, M. A., Cincotta, M., La Rosa, M., Guarino, R., Meo, A., & Frisina, N. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040113 · Cited by 127

RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma.

Roux, S., Meignin, V., Quillard, J., Meduri, G., Guiochon‐Mantel, A., Fermand, J., Milgrom, E., & Mariette, X. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03417.x · Cited by 125

Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma

Mazziotti, G., Sorvillo, F., Piscopo, M., Cioffi, M., Pilla, P., Biondi, B., Iorio, S., Giustina, A., Amato, G., & Carella, C. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041126 · Cited by 126

Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption

Gu, G., Mulari, M., Peng, Z., Hentunen, T. A., & Väänänen, H. K. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.211 · Cited by 123

Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

Akatsu, T., Murakami, T., Nishikawa, M., Ono, K., Shinomiya, N., Tsuda, E., Mochizuki, S.-I., Yamaguchi, K., Kinosaki, M., Higashio, K., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9294 · Cited by 123

Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.

Irie, A., Takami, M., Kubo, H., Sekino-Suzuki, N., Kasahara, K., & Sanai, Y. (2007) · Bone · doi:10.1016/j.bone.2007.04.190 · Cited by 116

Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand

Schneeweis, L. A., Willard, D., & Milla, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506366200 · Cited by 116

New Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target?

Tat, S. K., Pelletier, J.-P., Velasco, C. R., Padrines, M., & Martel-Pelletier, J. (2009) · The Keio Journal of Medicine · doi:10.2302/kjm.58.29 · Cited by 112

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption

Cawley, K. M., Bustamante-Gomez, N. C., Guha, A. G., MacLeod, R. S., Xiong, J., Gubrij, I., Liu, Y., Mulkey, R., Palmieri, M., Thostenson, J. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108052 · Cited by 114

Cross-Presentation by Osteoclasts Induces FoxP3 in CD8+ T Cells

Kiesel, J. R., Buchwald, Z. S., & Aurora, R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803897 · Cited by 109

Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.

Viereck, V., Gründker, C., Blaschke, S., Niederkleine, B., Siggelkow, H., Frosch, K.-H., Raddatz, D., Emons, G., & Hofbauer, L. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021877 · Cited by 110

Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.

Hakeda, Y., Kobayashi, Y., Yamaguchi, K., Yasuda, H., Tsuda, E., Higashio, K., Miyata, T., & Kumegawa, M. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9523 · Cited by 107

Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.

Atkins, G. J., Bouralexis, S., Haynes, D. R., Graves, S. E., Geary, S. M., Evdokiou, A., Zannettino, A. C. W., Hay, S., & Findlay, D. M. (2001) · Bone · doi:10.1016/s8756-3282(01)00404-5 · Cited by 105

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C. R., Stouch, B., Martin, S., & Kostenuik, P. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.852 · Cited by 103

Adenoviral Delivery of Osteoprotegerin Ameliorates Bone Resorption in a Mouse Ovariectomy Model of Osteoporosis

Bolon, B., Carter, C., Daris, M., Morony, S., Capparelli, C., Hsieh, A., Mao, M., Kostenuik, P., Dunstan, C. R., Lacey, D. L., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0245 · Cited by 100

The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1583 · Cited by 97

Paget’s disease of bone and genetic disorders of RANKL/OPG/RANK/NF-κB signaling.

WHYTE, M. P. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.016 · Cited by 95

Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.

Chikatsu, N., Takeuchi, Y., Tamura, Y., Fukumoto, S., Yano, K., Tsuda, E., Ogata, E., & Fujita, T. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.2008 · Cited by 95

DU145 human prostate cancer cells express functional receptor activator of NFκB: new insights in the prostate cancer bone metastasis process.

Mori, K., Le Goff, B., Charrier, C., Battaglia, S., Heymann, D., & Rédini, F. (2007) · Bone · doi:10.1016/j.bone.2006.11.006 · Cited by 95

Effect of smoking on serum RANKL and OPG in sex, age and clinically matched supportive‐therapy periodontitis patients

Lappin, D. F., Sherrabeh, S., Jenkins, W. M. M., & Macpherson, L. M. D. (2007) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2007.01048.x · Cited by 90

The origins and formation of bone-resorbing osteoclasts

Elson, A., Anuj, A., Barnea-Zohar, M., & Reuven, N. (2022) · Bone · doi:10.1016/j.bone.2022.116538 · Cited by 95

Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders

Workgroup, O. B. O. T. E. R. O. (., Carrillo-López, N., Martínez-Arias, L., Fernández-Villabrille, S., Ruiz-Torres, M. P., Dusso, A., Cannata-Andía, J. B., Naves-Díaz, M., & Panizo, S. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00803-2 · Cited by 91

Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.

Itoh, K., Udagawa, N., Matsuzaki, K., Takami, M., Amano, H., Shinki, T., Ueno, Y., Takahashi, N., & Suda, T. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.9.1766 · Cited by 90

RANKL Inhibition: A Novel Strategy to Decrease Femoral Head Deformity After Ischemic Osteonecrosis

Kim, H. K., Morgan-Bagley, S., & Kostenuik, P. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060905 · Cited by 89

Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy.

Akatsu, T., Murakami, T., Ono, K., Nishikawa, M., Tsuda, E., Mochizuki, S.-I., Fujise, N., Higashio, K., Motoyoshi, K., Yamamoto, M., et al. (1998) · Bone · doi:10.1016/s8756-3282(98)00141-0 · Cited by 87

Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.

Lai, F. P. L., Cole‐Sinclair, M., Cheng, W. ‐., Quinn, J. M. W., Gillespie, M. T., Sentry, J. W., & Schneider, H. ‐. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05018.x · Cited by 86

Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios.

J�rgensen, H. L., Kusk, P., Madsen, B., Fenger, M., & Lauritzen, J. B. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0461-3 · Cited by 85

Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis

Zheng, Y., Zhou, H., Brennan, K., Blair, J. M., Modzelewski, J. R. K., Seibel, M. J., & Dunstan, C. R. (2007) · Bone · doi:10.1016/j.bone.2006.09.016 · Cited by 82

Effects of receptor activator of NFκB (RANK) signaling blockade on fracture healing.

Flick, L. M., Weaver, J. M., Ulrich‐Vinther, M., Abuzzahab, F., Zhang, X., Dougall, W. C., Anderson, D., O'Keefe, R. J., & Schwarz, E. M. (2003) · Journal of Orthopaedic Research · doi:10.1016/s0736-0266(03)00011-1 · Cited by 82

Protein kinase N3 promotes bone resorption by osteoclasts in response to Wnt5a-Ror2 signaling

Uehara, S., Udagawa, N., Mukai, H., Ishihara, A., Maeda, K., Yamashita, T., Murakami, K., Nishita, M., Nakamura, T., Kato, S., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aan0023 · Cited by 83

Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice.

Samadfam, R., Xia, Q., & Goltzman, D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060915 · Cited by 80

Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis.

Campagnuolo, G., Bolon, B., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10369 · Cited by 78

Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity

Furuya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J. M., Nakamura, M., Udagawa, N., Aoki, K., Ohya, K., Uchida, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426080 · Cited by 77

Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.

Gannagé‐Yared, M., Fares, F., Semaan, M., Khalife, S., & Jambart, S. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02522.x · Cited by 76

Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.

Fahrleitner, A., Prenner, G., Leb, G., Tscheliessnigg, K. H., Piswanger-Sölkner, C., Obermayer-Pietsch, B., Portugaller, H. R., Berghold, A., & Dobnig, H. (2003) · Bone · doi:10.1016/s8756-3282(02)00926-2 · Cited by 71

Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget’s disease of bone.

Martini, G., Gennari, L., Merlotti, D., Salvadori, S., Franci, M. B., Campagna, S., Avanzati, A., De Paola, V., Valleggi, F., & Nuti, R. (2007) · Bone · doi:10.1016/j.bone.2006.08.003 · Cited by 72

Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells.

Hofbauer, L., Hicok, K., Chen, D., & Khosla, S. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470269 · Cited by 72

Osteoprotegerin mitigates tail suspension-induced osteopenia.

Bateman, T. A., Dunstan, C. R., Ferguson, V. L., Lacey, D. L., Ayers, R. A., & Simske, S. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00256-8 · Cited by 66

Osteoprotegerin is an effective countermeasure for spaceflight-induced bone loss in mice

Lloyd, S. A., Morony, S. E., Ferguson, V. L., Simske, S. J., Stodieck, L. S., Warmington, K. S., Livingston, E. W., Lacey, D. L., Kostenuik, P. J., & Bateman, T. A. (2015) · Bone · doi:10.1016/j.bone.2015.08.021 · Cited by 68

Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis

Skoumal, M., Kolarz, G., Haberhauer, G., Woloszczuk, W., Hawa, G., & Klingler, A. (2005) · Rheumatology International · doi:10.1007/s00296-004-0579-1 · Cited by 66

Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells.

Nakagawa, N., Yasuda, H., Yano, K., Mochizuki, S.-I., Kobayashi, N., Fujimoto, H., Shima, N., Morinaga, T., Chikazu, D., Kawaguchi, H., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1601 · Cited by 64

OPG/membranous–RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation

Tat, S. K., Padrines, M., Theoleyre, S., Couillaud-Battaglia, S., Heymann, D., Redini, F., & Fortun, Y. (2006) · Bone · doi:10.1016/j.bone.2006.03.016 · Cited by 63

Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.

Fahrleitner-Pammer, A., Dobnig, H., Piswanger-Soelkner, C., Bonelli, C., Dimai, H.-P., Leb, G., & Obermayer-Pietsch, B. (2003) · Wiener Klinische Wochenschrift · doi:10.1007/bf03040334 · Cited by 62

Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses

Stolina, M., Dwyer, D., Ominsky, M. S., Corbin, T., Van, G., Bolon, B., Sarosi, I., McCabe, J., Zack, D. J., & Kostenuik, P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7497 · Cited by 63

Semaphorin 3B Is a 1,25-Dihydroxyvitamin D3-Induced Gene in Osteoblasts that Promotes Osteoclastogenesis and Induces Osteopenia in Mice

Sutton, A. L. M., Zhang, X., Dowd, D. R., Kharode, Y. P., Komm, B. S., & MacDonald, P. N. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0363 · Cited by 61

The Progress about the Effect of Osteoprotegerin and its Ligand During Orthodontic Tooth Movement

Tang, L. (2007) · Medical Recapitulate

Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force

Keleş, A., Grunes, B., DiFuria, C., Gagari, E., Srinivasan, V., Darendeliler, M. A., Müller, R., Kent, R., & Stashenko, P. (2007) · European Journal Of Oral Sciences · doi:10.1111/j.1600-0722.2007.00433.x · Cited by 61

Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones

Woo, K. M., Choi, Y., Ko, S., Ko, J. S., Oh, K., & Kim, K.-K. (2002) · Experimental & Molecular Medicine · doi:10.1038/emm.2002.49 · Cited by 23

Regulation of osteoclast-mediated bone resorption by microRNA

Ji, L., Li, X., He, S., & Chen, S. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04298-y · Cited by 22

Tocotrienols Regulate Bone Loss through Suppression on Osteoclast Differentiation and Activity: A Systematic Review

Radzi, N. F. M., Ismail, N. A. S., & Alias, E. (2018) · Current Drug Targets · doi:10.2174/1389450119666180207092539 · Cited by 16